In a nutshell The study aimed to investigate the ability of dasatinib (Sprycel) to penetrate the brain in patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) at risk for central nervous system (CNS; brain and spinal cord) relapse. This study concluded that a dose of 140mg per day...
Read More
In a nutshell This study aimed to compare outcomes of donor types for a second allogeneic stem cell transplant (alloSCT) in patients with relapsed acute lymphoblastic leukemia (ALL). This study concluded that there is no major difference in overall survival between a matched unrelated donor (MUD) and a half-matched donor (HMD) in...
Read More
In a nutshell The study aimed to investigate the health-related quality of life (HR-QoL) for patients with chronic lymphocytic leukemia (CLL) who were treated with venetoclax (VEN; Venclexta) and obinutuzumab (Obi; Gazyva). This study concluded that this treatment is effective and does not impair the quality of life in these...
Read More
In a nutshell This study evaluated the safety and effectiveness of CAR T-cell therapy versus chemotherapy before a stem cell transplant (SCT) for patients with recurrent or non-responsive B-cell acute lymphoblastic lymphoma (B-ALL). The authors concluded that CAR T-cell therapy followed by SCT was safe and effective for these patients. Some background...
Read More
In a nutshell This study aimed to investigate the outcomes for patients with chronic lymphocytic leukemia (CLL), with genetic abnormalities (mutated IGHV) and without del(17p)/TP53 mutation, who were treated with the iFCG (ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab) regimen. This study concluded that this treatment regimen is...
Read More
In a nutshell This study aimed to investigate if a combination of inotuzumab ozogamicin (InO; Besponsa) and bosutinib (Bo; Bosulif) was safe and effective in patients with relapsed/refractory (r/r) Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL) or lymphoid blast phase (BP) chronic myeloid leukemia...
Read More
In a nutshell This study aimed to investigate long-term treatment-free remission (TFR) for patients with chronic-phase (CP) chronic myeloid leukemia (CML) who were treated with nilotinib (Tasigna) as a second-line treatment. This study concluded that TFR is safe and durable in these patients. Some background The...
Read More
In a nutshell This study aimed to compare outcomes for adolescents and young adults (AYA) with acute lymphoblastic leukemia (ALL) receiving chemotherapy or allogeneic hematopoietic stem cell transplantation (alloHSCT) after achieving complete remission. This study concluded that chemotherapy led to better outcomes for these patients when...
Read More
In a nutshell This study aimed to investigate the effectiveness of allogeneic hematopoietic stem cell transplantation (alloHSCT) in patients with chronic-phase chronic myeloid leukemia (CP-CML) who are resistant or intolerant to tyrosine kinase inhibitor (TKI) treatment. This study concluded that...
Read More
In a nutshell This study aimed to investigate if consolidation chemotherapy before reduced-intensity conditioning (RIC) allogeneic hemopoietic stem cell transplant (alloHSCT) improved outcomes for patients with acute myeloid leukemia (AML). This study concluded that exposure to consolidation chemotherapy before RIC alloHSCT may help patients...
Read More
In a nutshell This study aimed to investigate the prognostic value of measurable residual disease (MRD) in patients with acute myeloid leukemia (AML) who were treated with venetoclax (Venclexta) and decitabine (Dacogen). This study concluded that a negative MRD status after 1, 2, and 4 months of therapy predicts better...
Read More
In a nutshell This study aimed to investigate if restricting calories and nutrients from diet and exercise could change chemotherapy effectiveness in patients with B-cell acute lymphoblastic leukemia (ALL). This study concluded that restricting calories/nutrients via diet and exercise changed chemotherapy effectiveness and...
Read More
